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Abstract
Background: Modern radiotherapy plays an important role in therapy of advanced head and neck
carcinomas. However, no clinical studies have been published addressing the effectiveness of
postoperative radiotherapy in patients with small tumor (pT1, pT2) and concomitant ipsilateral
metastasis of a single lymph node (pN1), which would provide a basis for a general treatment
recommendation.
Methods/Design: The present study is a non-blinded, prospective, multi-center randomized
controlled trial (RCT). As the primary clinical endpoint, overall-survival in patients receiving
postoperative radiation therapy vs. patients without adjuvant therapy following curative intended
surgery is compared. The aim of the study is to enroll 560 adult males and females for 1:1
randomization to one of the two treatment arms (irradiation/no irradiation). Since patients with
small tumor (T1/T2) but singular lymph node metastasis are rare and the amount of patients
consenting to randomization is not predictable in advance, all patients rejecting randomization will
be treated as preferred and enrolled in a prospective observational study (comprehensive cohort
design) after giving informed consent. This observational part of the trial will be performed with
maximum consistency to the treatment and observation protocol of the RCT. Because the impact
of patient preference for a certain treatment option is not calculable, parallel design of RCT and
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observational study may provide a maximum of evidence and efficacy for evaluation of treatment
outcome. Secondary clinical endpoints are as follows: incidence and time to tumor relapse
(locoregional relapse, lymph node involvement and distant metastatic spread), Quality of life as
reported by EORTC (QLQ-C30 with H&N 35 module), and time from operation to orofacial
rehabilitation. All tumors represent a homogeneous clinical state and therefore additional
investigation of protein expression levels within resection specimen may serve for establishment
of surrogate parameters of patient outcome.
Conclusion: The inherent challenges of a rare clinical condition (pN1) and two substantially
different therapy arms would limit the practicality of a classical randomized study. The concept of
a Comprehensive Cohort Design combines the preference of a randomized study, with the option
of careful data interpretation within an observational study.
Trial registration: ClinicalTrials.gov: NCT00964977
Background
Ninety percent of all tumors in the head and neck region
are of squamous cell origin and world wide annual inci-
dence is estimated at 363.000 with a mortality of 200.000
[1,2]. Oropharyngeal squamous cell carcinoma (OSCC) is
the predominant malignancy in the head and neck region,
and is the seventh most frequently occurring tumor
world-wide. In the Federal Republic of Germany, up to 3-
5% of all malignant tumors are found within the oral cav-
ity and the oropharynx, with 7.500 new cases annually.
2.2% cases of death occur as a consequence of oropharyn-
geal malignancy [3]. Thus, treatment of patients with
OSCC is of great medical and economic importance. Pre-
vailing curative therapeutic strategies combine radical
resection of the tumor with a safety margin, followed by
radiation of the original tumor site and adjacent locore-
gional lymphatic drainage areas [4-6]. To date, selection
of the individual therapeutic pattern is essentially guided
by pre- and post-therapeutic TNM staging parameters.
Particularly for advanced tumors, postoperative radiother-
apy, possibly combined with chemotherapeutic agents, is
favorable and recommended [7-9]. Interdisciplinary
guidelines state the following detailed recommendations
for application of adjuvant radiation therapy:
- non in sano resection if reoperation is impossible
(R1-, R2-status)
- primary tumor status > pT2 and pN2, pN3
- extranodular spread of the disease
- lymphangiosis carcinomatosa
- facultative: pN1
According to these recommendations, postoperative radi-
otherapy of advanced tumors is advised, while for small
tumors the indication depends on further parameters
such as the pN- state. In these cases, verification of metas-
tasis in more than a single lymph node (pN2) leads to
additional radiotherapy. In tumors with a diameter of less
than 4 cm (T1, T2) and concomitant verification of a sin-
gle lymph node metastasis, no explicit therapeutic recom-
mendation is presently offered, leaving radiation as an
optional complement for these cases. Meta-Analysis
revealed only a few studies taking this special group of
patients into account, the results of which suggest that
adjuvant radiotherapy is an additional risk factor for over-
all survival. However, the small patient count, inhomoge-
neous group distribution and ambiguous risk factors in
these studies contribute to a substantial bias. Due to the
emerging importance of quality of life information, the
overall survival rate is not the only parameter of interest
when reviewing the effectiveness of modern tumor ther-
apy. Therefore, there is urgent need for controlled studies
verifying the effect of postoperative radiotherapy. The aim
of the present study is to investigate the clinical outcome
in patients with or without postoperative radiotherapy
after curative intended radical surgery, because meta-anal-
ysis of present retrospective clinical data failed to support
a safe and justifiable treatment regime in patients with
small tumor (T1, T2) and a single ipsilateral lymph node
metastasis.
The following key methodological problems have to be
addressed in the protocol:
￿ extremely different treatment arms with strong pref-
erences for one or the other therapy arm
￿ low number of eligible patients per center
￿ Inclusion criterion (pN1), including a pathological
diagnosis and surgical treatment with possible differ-
encesTrials 2009, 10:118 http://www.trialsjournal.com/content/10/1/118
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￿ Radiation treatment as one arm with special quality
control needs
The purpose of presenting this paper is to discuss how
these specific issues were addressed.
Methods/Design
Study Design
The study is designed as a non-blinded, prospective, ran-
domized controlled clinical trial. Study approval was
given by the Ethics Committee of the State Medical Coun-
cil of Rhineland-Palatinate, Germany [Ref. No:
837.148.03 (3810)]. As part of the Johannes Gutenberg-
University, the Coordination Center for Clinical Trials
(KKS Mainz, Germany), will monitor the study progress
and assure data accuracy. Obvious side effects of radiation
therapy render blinding of patients and examiner impos-
sible.
Study objectives
The objective of the clinical study will be to investigate
two different patient groups (irradiated/unirradiated)
with pT1/2 primary and verification of a singular ipsilat-
eral lymph node metastasis in parallel design in order to
evaluate the possible benefit of radiation therapy. Subse-
quent investigation of biological parameters will be per-
formed to assess the capacity to predict tumor progression
and to evaluate surrogate markers of radioresistance. The
following null hypothesis forms the basis of the present
study: Radiation therapy will have no influence on the
overall survival in patients with pT1/2, pN1 primary
tumor. Secondary outcome variables include incidence
and time to tumor relapse (locoregional relapse, lymph
node involvement and metastatic spread), Quality of life
as reported by EORTC (QLQ-C30 with H&N 35 module)
and time from operation to orofacial rehabilitation.
Patients
Males and females with a histologically verified diagnosis
of a primary squamous cell carcinoma of the oral cavity or
the oropharynx are eligible. Inclusion criteria are as fol-
lows:
- maximum tumor diameter less than 4 cm in the
pathohistological specimen irrespective of histological
grading (pT1 or pT2)
- concomitant histological verification of a singular
ipsilateral lymph node metastasis less than 3 cm in
diameter (pN1) without penetration of the lymph
node's capsule and without presence of lymphangiosis
carcinomatosa
- radical resection of the tumor within adequate resec-
tion margins (R0)
- written informed consent from the patient
- adequate performance status ECOG Index ≤ 2
Patients younger than 18 and pregnant women are to be
excluded. Further criteria of exclusion are reported drug
addiction or intake of remedies with a potential influence
on compliance or impaired judgment. In addition,
patients with familial or job related responsibilities which
may preclude the patient from maintaining the study
schedule, as well as patients with inadequately treated dis-
eases, such as untreated diabetes mellitus or acute heart
insufficiency (ECOG-Index>2), will also be excluded.
Study interventions
Radiotherapy should begin within 6 weeks after the last
surgical intervention while respecting a minimal postop-
erative healing period of at least 8 days. Causes for delay
of intervention are to be documented. In both the RCT
and observational study, patients of group 1 will be
treated by irradiation and patients of group 2 will not
receive radiotherapy.
Surgical treatment
The primary tumor is considered radically resected if mac-
roscopic and histologic evaluation shows resection mar-
gins without tumor residuals (R0 status). For surgical
proceeding, a safety margin of at least 0.5 cm is estab-
lished. Lymph node resection will be oriented in relation
to the tumor center, which can be localized in level I
(below occlusional plane) or level II (above occlusional
plane), in addition to being precanine, postcanine or ret-
romolar (Figure 1). Infiltration of the periosteum and
midline crossing is also characterized. Classification of
cervical regions follows the recommendations of Robbins
from 2002 [10]. Hence, the neck is divided into 6 different
sections (Figure 2).
Ipsilateral N0 state of cervical lymph nodes
Pre- and post-canine localized tumors of level I require
selective neck dissection of the cervical level 1-3. For Level
I tumors of the retromolar triangle selective neck dissec-
tion of ipsilateral level 1-5 is proceeded. For level II
tumors no selective neck dissection is considered.
Contralateral N0 state
No neck dissection is performed
Ipsilateral N1-N2 state
For retromolar localized level I tumors, a modified radical
neck dissection is performed. If the tumor is localized,
pre- or post-canine, intraoperative frozen sections of level
1 lymph nodes are evaluated. Positive intraoperative
results lead to modified radical resection of level 1-5
lymph nodes, while negative results only require resectionTrials 2009, 10:118 http://www.trialsjournal.com/content/10/1/118
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According to Bier (1982) description of tumor position follows its relation to the occlusal plane, canine and the last molar in  transversal, saggital and axial projection Figure 1
According to Bier (1982) description of tumor position follows its relation to the occlusal plane, canine and the 
last molar in transversal, saggital and axial projection.Trials 2009, 10:118 http://www.trialsjournal.com/content/10/1/118
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of the lymph nodes within level 1-3. Negative intraopera-
tive frozen sections in level II tumors require no lymph
node dissection, but all metastatic affection of level II-III
lymph nodes lead to modified radical neck dissection.
Contralateral N1-N2 state
Frozen sections will be performed for level 1 lymph
nodes. Modified radical neck dissection is performed in
positive results, resection of level 1-3 lymph nodes is con-
ducted in case of negative results. Incidence of metastasis
in level 2-3 lymph nodes acquire modified radical neck
dissection.
Lymph node therapy of midline tumors
Midline tumors require bilateral resection of lymph node
echelons at risk. Bilateral modified neck dissection is per-
formed for staging purposes if indicated. Contralateral
lymph node dissection of the level 1-3 in precanine local-
ized tumors is mandatory.
Technical conditions and practical execution of radiation 
therapy
Radiotherapy is performed using photons of 4 to10 MeV
or/and electrons of 6 to 15 MeV maximum energy. Indi-
vidual 3-dimensional dose distribution calculations are
mandatory and have to be made on the basis of a postop-
erative native computer tomography. All patients are to be
treated while immobilized by a custom made face mask
made of thermoplast or equivalent. Clinical target volume
definition encompasses the original tumor site with a
safety margin of 2 cm in each direction.
Floor of mouth, anterior tongue
Irradiation of the anterior two third of the tongue as well
as the anterior floor of mouth is irradiated by laterally
opposing beams, while the maxilla is separated by inser-
tion of a bite block.
Oropharynx, buccal plane, soft palate confined to one side
For tumors of the buccal plane, the tonsilla, the soft palate
and the retromolar triangle, two types of target volume
planning may be applied.
An ipsilateral target volume for the primary is defined,
including the lymph nodes of group IB, IIA and IIB. The
irradiation technique recommended uses two wedge
fields, typically angulated by 90 to 120 degrees. The ipsi-
lateral node levels III-V are treated by an anterior portal
down to the clavicle, while the contralateral neck is
spared.
Tumors of the lateral and dorsal pharyngeal wall and their
lymphatic drainage (levels II, III, IV and V) are irradiated
bilaterally with opposing beams. Irrespective of technique
used, 3-D conformal dose shaping is highly recom-
mended.
Dosage and fractionation
Target volume definition and dosage must be performed
according to the rules of ICRU report 50. At the primary
tumor site and at involved lymph node levels, a total dose
of 59.4 Gy in 33 fractions within 45 days is scheduled, and
for electively irradiated volumes, a total dose of 50.4 Gy in
28 fractions is scheduled. All fractions of 1.8 Gy are given
five times per week. In case of machine break down, an
additional fraction per week is recommended with a min-
imum 6 h interval between two fractions on the same day
or on Saturday. Total treatment duration (including
planned/unplanned interruptions) is to be documented
in days. All patients must be available for intent to treat
analysis.
Instead of the classical portal arrangements and dose dis-
tributions, intensity modulated radiotherapy using an
inverse calculation algorithm may be used in experienced
centers. Dose constraints for normal tissues are left to the
discretion of the participating centers, but dose specifica-
tion according to the RTOG protocol H 0022 is recom-
mended [11]. These details will be given in a standard
operation procedure.
Follow-Up
The recruitment phase will last 4 years. The follow up will
include physical examinations, ECOG index, and quality
of life questionnaires collected at 3, 6 and 12 months post
operative. Further follow up will be performed annually
until the study end. This means that patients will be fol-
Definition of the cervival levels as defined by Robbins 1991 Figure 2
Definition of the cervival levels as defined by Robbins 
1991.Trials 2009, 10:118 http://www.trialsjournal.com/content/10/1/118
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lowed up for a minimum of 5 years and a maximum of 9
years.
Randomization and Sample Size
The present study design consists of a two-armed, rand-
omized controlled trial (RCT), but patients who refuse to
participate in a randomized approach and who express a
radiation preference will be included in a prospective
observational study after giving informed consent. This
parallel observational trial will follow the same treatment
and observation protocol as the RCT. Patients who agree
to the randomized trial will be randomized and stratified
according to lymph node therapy (yes/no) as formulated
by the DOESAK [12]. Randomization to the radiation
group and control group will be done 1 to 1, with recruit-
ment extending over a period of 4 years and ongoing,
annual follow-up continuing until the trial ends, i.e. for at
least 5 years for each patient. Sample size calculation will
be performed for the two-sided log rank test at a signifi-
cance level of 5%. Assuming exponential distributed sur-
vival with 45% survival within the control group and 55%
within the radiation group after 5 years (as per results
observed in the DOESAK collective), and a drop-out rate
of 5% per year, 280 patients per group are required to
detect a difference of 5% in overall survival with a power
of 70%. To ensure proper power adjustment, an interme-
diate analysis of the true drop out rate will be conducted.
Recruitment of at least 280 patients per group in the
observational study will be pursued only in the unfortu-
nate event that patient recruitment within the rand-
omized trial fails.
Analysis of RCT and observational trial
Carrying out this RCT is only justifiable if there is a realis-
tic chance of enrolling enough patients to complete a
meaningful statistical analysis. Therefore, an intermediate
assessment of the randomized patient population will be
performed after the first and second years of recruitment.
If the numbers are deemed to be insufficient, additional
study sites will be added and a web-based information
platform will be launched in the hopes of garnering addi-
tional attention from affected patients and physicians.
If less than 5% of patients agreed to randomization within
the first year and less than 10% within the second year,
the RCT will be stopped and continued solely as an obser-
vational trial (see Table 1). Due to the dual study design
(parallel RCT and observational cohort), the following
analysis scenarios are possible:
1) If a sufficient number of patients consent to randomi-
zation, treatment comparison will be performed within
the randomized arms. The non-randomized cohort will
be used to evaluate the external validity of observed treat-
ment effects according to Schmoor et. al. [11].
2) If a sufficient number of patients cannot be rand-
omized, all recruited patients will be analyzed. Descrip-
tive comparison of treatment groups will be performed for
all baseline variables. All analyses will be performed with
adjustment to baseline variables affecting survival. Results
will be interpreted with respect to any group differences in
baseline variables. This study setup was first described by
Schmoor et al. as a comprehensive cohort study design
[13].
Outcome measurements
The primary analysis will be an intention to treat analysis
on the randomized subjects.
Table 1: Time Schedule
Start -> Start of recruitment phase (presumably Sep. 2009)
End of year 1 ->Intermediate assessment of recruitment level:
- If fraction of randomized patients <5% of total count: ongoing recruitment, else abortion of randomization
End of year 2 ->Second intermediate assessment of recruitment level:
- If fraction of randomized patients <10% of total count: ongoing recruitment, else abortion of randomization





End of year 9 -> End of Follow-Up
-> Final analysis of the primary clinical endpoint: Evaluation of the overall-survivalTrials 2009, 10:118 http://www.trialsjournal.com/content/10/1/118
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Primary clinical endpoint
Overall survival at the end of the study
Secondary clinical endpoints
Incidence of tumor relapse
- Time to occurrence of lymphatic metastases
- Time to occurrence of local relapse
- Time to occurrence of distant metastasis
- Tumor related death due to local tumor progression
or metastatic spread
Life quality
 Time to provisional orofacial rehabilitation
 Time from operation to first intermediate pros-
thesis intake
 Time from operation to definitive prosthesis
application
 Life Quality report (EORTC QLQ-C30 with H&N
35 module)
Metabolic factors
Since the patients involved have equal tumor states,
immunohistological investigation of protein expression
levels of paraffin embedded sections may help to establish
surrogate parameters of radioresistance in oral squamous
cell carcinoma. The following factors are to be considered:
ki-67, GLUT-1, Hif-1alpha, MCT-1, p53-family members,
RB/p130, adhaesion molecules, cytokine and cytokine-
receptor expression (IL-2/IL2R_), eIF4E. Pathohistologi-
cal evaluation of tumor host interaction will be described
by vessel density, amount of infiltration by dendritic cells
and macrophages, and chain expression in TIL, Fas/FasL-
Expression.
Statistical analysis
Overall survival will be evaluated using a Cox propor-
tional hazard model with treatment and adequate lymph
node therapy (yes/no) as covariates. Further covariates
may be considered if they affect survival. Statistical analy-
sis will be done with SAS and SPSS® (Statistical Package for
Social Science) software for Windows (Chicago, II USA).
The Institute of Medical Biostatistics, Epidemiology and
Informatics (IMBEI) at the University Medical Center of
the Johannes-Gutenberg-University Mainz will provide
advice for statistical analysis.
Discussion
Randomized (blinded) clinical trials represent the gold
standard for comparison of treatment efficacy as postu-
lated by the criteria of modern evidenced based medicine
[14]. Therefore, RCTs are desired to establish "Grade A"
treatment recommendations. A key advantage of rand-
omization is the equal distribution of known and
unknown confounding variables within intervention
groups, and the elimination of their influence on the out-
come [15]. Only the experimental design of a RCT reduces
the otherwise unavoidable risk of selection bias and sys-
tematic differences which are not induced by the treat-
ment itself, but may affect the outcome. Thus, the study
described in this paper could provide a reliable, unbiased
appraisal of radiation effectiveness. However, field experi-
ence from studies with strongly differing therapy regimens
have shown that randomization might fail due to a strong
preference of patient and/or physician for a certain thera-
peutic option (preference effect) [15-17]. Within the "Ger-
man Breast Cancer Study Group" (GBSG) which
investigated operation vs. radiation, only 6.4% of eligible
patients consented to randomization [18,19]. Conducting
such a study as RCT might not be suitable as a source of
evidence due to essential loss of statistical power. External
generalization of such data might be harmful if compari-
son to the intended target population is not supported by
a sufficient patient count. Unfortunately the magnitude of
the preference effect can not be estimated in advance,
although its occurrence in the present study is highly
probable due to similarities to the German Breast Cancer
Study Group. Thus, the present study setup also uses a
comprehensive cohort design. In the unfortunate event
that the study fails as a RCT, the obtained clinical data will
still allow careful evaluation of radiation effectiveness
under controlled conditions in specialist centers. Further-
more, this valuable clinical data might serve as a useful
guide for the design of controlled clinical trials in the
future. Using a comprehensive cohort design, Raus-
checker et al. enrolled more than 1000 patients within the
"German Breast Cancer Study Group" (GBSG), and pre-
sented a valuable outcome after a long observational
period [19].
Further key methodological aspects included differing
therapeutic regimens between the study centers, as varying
surgical strategies may result in a performance bias with
influence on the outcome [20]. The variability of surgical
procedures in the head and neck area for control of loco-
regional relapse and lymph node involvement is high
[21,22]. Thus balanced randomization with stratification
by the surgical treatment recommendations of Bier [12]
serves for additional improvement of internal validity. In
addition, radiation therapy is a well established subse-
quent therapeutic option for patients with advanced head
and neck cancer, whereas a positive effect for the T1-2N1
neck is still open to evaluation [7]. Similar to surgery,
diverse radiation protocols and additional physical con-
siderations necessitate a singular treatment center to
ensure quality control as crucial aspect of quality assur-
ance for the present study.Publish with BioMed Central    and   every 
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Conclusion
Under the constraints of a rare condition (pN1) and two
substantially differing therapy arms, the practicality and
obtainable evidence of a classical randomized study are
challenged. The concept of a "Comprehensive Cohort
Design" includes the option of a randomized study with
an observational study as a backup if randomization of
patients fails due to a strong preference effect.
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